Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-Field I
NCT07057089Phase 2Suspended
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Jul 2025
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in rectal cancer, sponsored by The Fourth Hospital of Hebei Medical University. Started Jul 2025; status: suspended.
02
Drugs
camrelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07057089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07057089.